Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON24500
NL-OMON24500
Recruiting
Not Applicable

Integrated Biomarker and Imaging Study: To Assess the Ability of Rosuvastatin to Decrease Necrotic Core in Coronary Arteries.

Erasmus Medical center (Thoraxcenter)0 sites300 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCoronary artery disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary artery disease
Sponsor
Erasmus Medical center (Thoraxcenter)
Enrollment
300
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Erasmus Medical center (Thoraxcenter)

Eligibility Criteria

Inclusion Criteria

  • •1\. More than 18 years old;
  • •2\. Written informed consent;

Exclusion Criteria

  • •1\. Braunwald class IA, IIA, IIIA (unstable angina caused by non\-cardiac illness);
  • •2\. Women who are pregnant or women of childbearing potential who do not use adequate contraception;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2
EUCTR2005-001556-20-CZGlaxoSmithKline Research & Development Limited300
Active, not recruiting
Phase 1
Integrated Biomarker and Imaging Study – 2 (IBIS-2)Estudio integrado de biomarcadores y técnicas de imagen - 2 (IBIS-2) - IBIS-2
EUCTR2005-001556-20-ESGlaxoSmithKline, S.A.
Active, not recruiting
Not Applicable
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2
EUCTR2005-001556-20-ATGlaxoSmithKline Research & Development Limited300
Active, not recruiting
Phase 1
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
EUCTR2005-001556-20-GBGlaxoSmithKline Research & Development Limited
Active, not recruiting
Not Applicable
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
EUCTR2005-001556-20-DKGlaxoSmithKline Research & Development Limited300